Unlike traditional treatments that block the function of dysregulated proteins, degraders remove them entirely, reports Dr Shuai Wu, Professorial Researcher at WuXi AppTec.
This provides access to a new frontier in the development of interventions for proteins that were previously considered to be “undruggable.”
But for every new class of therapeutics, two questions quickly follow its discovery: what testing methods should be used to ensure the safety and efficacy of this new treatment modality and how do we validate those methodologies?
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.